We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
- Authors
Samur, Mehmet Kemal; Fulciniti, Mariateresa; Aktas Samur, Anil; Bazarbachi, Abdul Hamid; Tai, Yu-Tzu; Prabhala, Rao; Alonso, Alejandro; Sperling, Adam S.; Campbell, Timothy; Petrocca, Fabio; Hege, Kristen; Kaiser, Shari; Loiseau, Hervé Avet; Anderson, Kenneth C.; Munshi, Nikhil C.
- Abstract
BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined. Here, we perform single cell genomic characterization of longitudinal samples from a patient who relapsed after initial CAR T cell treatment with lack of response to retreatment. We report selection, following initial CAR T cell infusion, of a clone with biallelic loss of BCMA acquired by deletion of one allele and a mutation that creates an early stop codon on the second allele. This loss leads to lack of CAR T cell proliferation following the second infusion and is reflected by lack of soluble BCMA in patient serum. Our analysis suggests the need for careful detection of BCMA gene alterations in multiple myeloma cells from relapse following CAR T cell therapy. Relapse following BCMA targeted CAR T-cell therapy is frequently observed in patients with multiple myeloma (MM). Here, by single cell transcriptome profiling on serially collected bone marrow samples, the authors report biallelic loss of BCMA as the mechanism of resistance underlying both relapse and lack of response to a second CAR T infusion in a patient with MM.
- Subjects
T cells; MULTIPLE myeloma; CELLULAR therapy; CHIMERIC antigen receptors; BONE marrow
- Publication
Nature Communications, 2021, Vol 12, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-021-21177-5